论文部分内容阅读
目的观察依达拉奉治疗急性脑梗死临床疗效及对超敏反应蛋白(hs-CRP)的影响。方法选取医院2014年2月-2015年2月收治的急性脑梗死患者68例,按照入院顺序分为观察组与对照组各34例,对照组采取常规的辛伐他汀、阿司匹林片等药物治疗,观察组在此基础上予以依达拉奉静脉滴注,对2组患者在治疗后第7天和第14天按照欧洲卒中量表进行卒中评分(NIHSS),并测定其hs-CRP水平。结果在治疗后第7天、和第14天,观察组NIHSS评分和hs-CRP水平下降明显明显高于对照组,差异有统计学意义(P<0.05);观察组总有效率为91.18%明显高于对照组的64.70%,差异有统计学意义(P<0.05)。结论依达拉奉在急性脑梗死患者的临床治疗中具有显著的效果,并能对hs-CRP起到抑制作用,减轻患者的炎症反应,值得临床推广。
Objective To observe the clinical efficacy of edaravone in the treatment of acute cerebral infarction and its effect on hs-CRP. Methods Sixty-eight patients with acute cerebral infarction admitted from February 2014 to February 2015 in our hospital were divided into observation group (34 cases) and control group (34 cases) according to the order of admission. The control group was treated with conventional simvastatin and aspirin tablets, On the basis of this, intravenous infusion of edaravone was given to the observation group. Stroke score (NIHSS) was measured on the 7th and 14th days after treatment in both groups in accordance with the European Stroke Scale, and the level of hs-CRP was measured. Results On the 7th day and the 14th day after treatment, the NIHSS score and the hs-CRP level in the observation group were significantly lower than those in the control group (P <0.05). The total effective rate in the observation group was 91.18% Higher than 64.70% of the control group, the difference was statistically significant (P <0.05). Conclusion Edaravone has a significant effect in the clinical treatment of patients with acute cerebral infarction, hs-CRP can inhibit and reduce the inflammatory response in patients, it is worth clinical promotion.